FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1956520512> ?p ?o ?g. }

• W1956520512 endingPage "4503" @default.
• W1956520512 startingPage "4497" @default.
• W1956520512 abstract "Annually, medical device infections are associated with >250,000 catheter-associated bloodstream infections (CLABSI), with up to 25% mortality. Staphylococcus aureus, a primary pathogen in these infections, is capable of biofilm production, allowing organism persistence in harsh environments, offering antimicrobial protection. With increases in S. aureus isolates with reduced susceptibility to current agents, ceftaroline (CPT) offers a therapeutic alternative. Therefore, we evaluated whether CPT would have a role against biofilm-producing methicillin-resistant S. aureus (MRSA), including those with decreased susceptibilities to alternative agents. In this study, we investigated CPT activity alone or combined with daptomycin (DAP) or rifampin (RIF) against 3 clinical biofilm-producing MRSA strains in an in vitro biofilm pharmacokinetic/pharmacodynamic (PK/PD) model. Simulated antimicrobial regimens were as follows: 600 mg of CPT every 8 h (q8h) (free maximum concentration of drug [fCmax], 17.04 mg/liter; elimination half-life [t1/2], 2.66 h), 12 mg/kg of body weight/day of DAP (fCmax, 14.7 mg/liter; t1/2, 8 h), and 450 mg of RIF q12h (fCmax, 3.5 mg/liter; t1/2, 3.4 h), CPT plus DAP, and CPT plus RIF. Samples were obtained and plated to determine colony counts. Differences in log10 CFU/cm(2) were evaluated by analysis of variance with Tukey's post hoc test. The strains were CPT and vancomycin susceptible and DAP nonsusceptible (DNS). CPT displayed activity throughout the experiment. DAP demonstrated initial activity with regrowth at 24 h in all strains. RIF was comparable to the drug-free control, and little benefit was observed when combined with CPT. CPT plus DAP displayed potent activity, with an average log10 CFU/cm(2) reduction of 3.33 ± 1.01 from baseline. CPT demonstrated activity against biofilm-producing DNS MRSA. CPT plus DAP displayed therapeutic enhancement over monotherapy, providing a potential option for difficult-to-treat medical device infections." @default.
• W1956520512 created "2016-06-24" @default.
• W1956520512 creator A5019624240 @default.
• W1956520512 creator A5041850762 @default.
• W1956520512 creator A5060754459 @default.
• W1956520512 creator A5079017304 @default.
• W1956520512 creator A5084829703 @default.
• W1956520512 creator A5085741336 @default.
• W1956520512 date "2015-08-01" @default.
• W1956520512 modified "2023-10-12" @default.
• W1956520512 title "Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model" @default.
• W1956520512 cites W1989942811 @default.
• W1956520512 cites W2006574476 @default.
• W1956520512 cites W2033028168 @default.
• W1956520512 cites W2067928590 @default.
• W1956520512 cites W2079575346 @default.
• W1956520512 cites W2080708358 @default.
• W1956520512 cites W2087865186 @default.
• W1956520512 cites W2098995708 @default.
• W1956520512 cites W2106351298 @default.
• W1956520512 cites W2112167903 @default.
• W1956520512 cites W2113742076 @default.
• W1956520512 cites W2115486016 @default.
• W1956520512 cites W2119104982 @default.
• W1956520512 cites W2122836009 @default.
• W1956520512 cites W2125603952 @default.
• W1956520512 cites W2126915534 @default.
• W1956520512 cites W2127913430 @default.
• W1956520512 cites W2131727615 @default.
• W1956520512 cites W2133736791 @default.
• W1956520512 cites W2138194474 @default.
• W1956520512 cites W2141948883 @default.
• W1956520512 cites W2144195043 @default.
• W1956520512 cites W2150371194 @default.
• W1956520512 cites W2151547308 @default.
• W1956520512 cites W2155311152 @default.
• W1956520512 cites W2167218440 @default.
• W1956520512 cites W2168625432 @default.
• W1956520512 cites W2169203610 @default.
• W1956520512 cites W2170634826 @default.
• W1956520512 cites W4230543984 @default.
• W1956520512 cites W4292156439 @default.
• W1956520512 doi "https://doi.org/10.1128/aac.00386-15" @default.
• W1956520512 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4505217" @default.
• W1956520512 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25987623" @default.
• W1956520512 hasPublicationYear "2015" @default.
• W1956520512 type Work @default.
• W1956520512 sameAs 1956520512 @default.
• W1956520512 citedByCount "37" @default.
• W1956520512 countsByYear W19565205122015 @default.
• W1956520512 countsByYear W19565205122016 @default.
• W1956520512 countsByYear W19565205122017 @default.
• W1956520512 countsByYear W19565205122018 @default.
• W1956520512 countsByYear W19565205122019 @default.
• W1956520512 countsByYear W19565205122020 @default.
• W1956520512 countsByYear W19565205122021 @default.
• W1956520512 countsByYear W19565205122022 @default.
• W1956520512 countsByYear W19565205122023 @default.
• W1956520512 crossrefType "journal-article" @default.
• W1956520512 hasAuthorship W1956520512A5019624240 @default.
• W1956520512 hasAuthorship W1956520512A5041850762 @default.
• W1956520512 hasAuthorship W1956520512A5060754459 @default.
• W1956520512 hasAuthorship W1956520512A5079017304 @default.
• W1956520512 hasAuthorship W1956520512A5084829703 @default.
• W1956520512 hasAuthorship W1956520512A5085741336 @default.
• W1956520512 hasBestOaLocation W19565205121 @default.
• W1956520512 hasConcept C111113717 @default.
• W1956520512 hasConcept C112705442 @default.
• W1956520512 hasConcept C126322002 @default.
• W1956520512 hasConcept C176674119 @default.
• W1956520512 hasConcept C176947019 @default.
• W1956520512 hasConcept C2777052132 @default.
• W1956520512 hasConcept C2777334864 @default.
• W1956520512 hasConcept C2778651397 @default.
• W1956520512 hasConcept C2778980435 @default.
• W1956520512 hasConcept C2779489039 @default.
• W1956520512 hasConcept C2780950330 @default.
• W1956520512 hasConcept C4937899 @default.
• W1956520512 hasConcept C501593827 @default.
• W1956520512 hasConcept C523546767 @default.
• W1956520512 hasConcept C54355233 @default.
• W1956520512 hasConcept C58123911 @default.
• W1956520512 hasConcept C71924100 @default.
• W1956520512 hasConcept C86803240 @default.
• W1956520512 hasConcept C89423630 @default.
• W1956520512 hasConcept C98274493 @default.
• W1956520512 hasConceptScore W1956520512C111113717 @default.
• W1956520512 hasConceptScore W1956520512C112705442 @default.
• W1956520512 hasConceptScore W1956520512C126322002 @default.
• W1956520512 hasConceptScore W1956520512C176674119 @default.
• W1956520512 hasConceptScore W1956520512C176947019 @default.
• W1956520512 hasConceptScore W1956520512C2777052132 @default.
• W1956520512 hasConceptScore W1956520512C2777334864 @default.
• W1956520512 hasConceptScore W1956520512C2778651397 @default.
• W1956520512 hasConceptScore W1956520512C2778980435 @default.
• W1956520512 hasConceptScore W1956520512C2779489039 @default.
• W1956520512 hasConceptScore W1956520512C2780950330 @default.
• W1956520512 hasConceptScore W1956520512C4937899 @default.

• next